加昧逍遥散治疗抑郁症对照研究

目的探讨加味逍遥散治疗抑郁症的临床疗效和安全性。方法将80例抑郁症患者随机分为两组，每组40例，观察组口服加味逍遥散汤剂治疗，对照组口服舍曲林治疗，观察2个月。于治疗前及治疗2个月末，采用Zung抑郁自评量表、中医症候量表评定临床疗效，同时检查血常规，尿、大便常规，肝、肾功能，心电图等。结果治疗2个月末两组Zung抑郁自评量表及中医症候量表评分均较治疗前显著下降（P〈0．01）；治疗前两组Zung抑郁自评量表及中医症候量表评分比较差异均无显著性（P〉0．05），治疗后观察组中医症候量表评分显著低于对照组（P〈0．05），Zung抑郁自评量表评分与对照比较差异无显著性（P〉0．05）；观察组有效率为87．5％，对照组为89．7％，两组比较差异无显著性（x2=0．10，P〉0．05）。两组不良反应均轻微，各项辅助检查均未发现异常。结论加味逍遥散与舍曲林治疗抑郁症疗效均显著，安全性高，依从性好，但加味逍遥散改善患者郁病症候方面优于舍曲林，更有利于提高患者的治疗依从性。

A control study of modified Xiaoyao San in the treatment of depression

Objective To explore the efficacy and safety of modified Xiaoyao San in the treatment of de- pression. Methods Eighty depression patients were randomly assigned to two groups of 40 one each, ob- servation group took orally modified Xiaoyao San decoctions and control group did sertraline for two months. Efficacies were assessed with the Self-rating Depression Scale （SDS） and Symptoms Lists of Tra- ditional Chinese Medicine （SLTCM） at baseline and at the end of 2 month treatment, meanwhile blood, u- rine and stool routine, liver and renal function and ECG detected. Results At the end of 2 month treat- ment the SDS and SLTCM scores of both groups lowered more significantly compared with pretreatment （P〈0.01） ; before treatment there were no significant differences in both SDS and SLTCM scores between two groups （P〉0.05）, after treatment the SLTCM score was significantly lower in observation than in control group （P〈0.05）, there was no significant difference in SDS score （P〉0.05） ; effective rates were respectively 87.5% in observation and 89.7% in control group, which showed no significant difference （x2=0.10, P〉0.05）. Adverse reactions of both groups were mild, all auxiliary examinations had no ab- normal findings. Conclusion Both modified Xiaoyao San and sertraline have an evident effect, higher safe- ty and better compliance in depression, but the former has advantages in improving depressive symptoms and raising patients＇ treatment compliance over the latter.